Recent advancement of gelatin nanoparticles in drug and vaccine delivery

International Journal of Biological Macromolecules

Volumn 81, Issue , 2015, Pages 317-331

  Sahoo, Nityananda ^a   Sahoo, Ranjan Ku ^a   Biswas, Nikhil ^a   Guha, Arijit ^a   Kuotsu, Ketousetuo ^a  

^a JADAVPUR UNIVERSITY   (India)

Author keywords

Entrapment efficacy; Gelatin nanoparticles; Vaccine delivery

Indexed keywords

AMPHOTERICIN B; BOVINE SERUM ALBUMIN; CHLORAMINE DERIVATIVE; CHOLAMINCHLORIDE; CISPLATIN; CYCLOHEXIMIDE; CYCLOSPORIN; CYTARABINE; DIDANOSINE; DOXORUBICIN; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; GELATIN NANOPARTICLE; HYDROCORTISONE; IBUPROFEN; MACROGOL; METHOTREXATE; NANOPARTICLE; PACLITAXEL; PILOCARPINE; RESVERATROL; RIFAMPICIN; ROSIGLITAZONE; SULFAMETHOXAZOLE; TELMISARTAN; UNCLASSIFIED DRUG; VALSARTAN; DRUG CARRIER; GELATIN; VACCINE;

BIODEGRADABILITY; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; ENTRAPMENT EFFICACY; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NANOPRECIPITATION; NONHUMAN; PARTICLE SIZE; PHYSICAL PARAMETERS; POLYDISPERSITY INDEX; PRECIPITATION; REVIEW; SUSTAINED DRUG RELEASE; ZETA POTENTIAL; ANIMAL; CHEMISTRY; DRUG RELEASE; GENE TRANSFER; IMMUNOLOGY; MEDICINAL CHEMISTRY; PROCEDURES; SURFACE PROPERTY;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG LIBERATION; GELATIN; GENE TRANSFER TECHNIQUES; HUMANS; NANOPARTICLES; SURFACE PROPERTIES; VACCINES;

EID: 84955497965     PISSN: 01418130     EISSN: 18790003     Source Type: Journal    
DOI: 10.1016/j.ijbiomac.2015.08.006     Document Type: Review

References (186)

1. Mohanty B., Aswal V.K., Kohlbrecher J., Bohidar H.B. Synthesis of gelatin nanoparticles via simple coacervation. J. Surf. Sci. Technol. 2005, 21:149-160.
2. Saraogi G.K., Gupta P., Gupta U.D., Jain N.K., Agrawal G.P. Gelatin nanocarriers as potential vectors for effective management of tuberculosis. Int. J. Pharm. 2010, 385:143-149.
3. Kumari A., Yadav S.K., Yadav S.C. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf. B 2010, 75:1-18.
4. Elzoghby A.O., Samy W.M., Elgindy N.A. Protein based nanocarriers as promising drug and gene delivery systems. J. Control. Release. 2012, 161:38-49.
5. Veis A. The Macromolecular Chemistry of Gelatin 1964, Academic Press, New York. 1st ed.
6. Weber C., Coester C., Kreuter J., Langer K. Desolvation process and surface characterization of protein nanoparticles. Int. J. Pharm. 2000, 194:91-102.
7. Fries W. Collagen-biomaterial for drug delivery. Eur. J. Pharm. Biopharm. 1998, 45:113-136.
8. Patel Z.S., Yamamoto M., Ueda H., Tabata Y., Mikos A.G. Biodegradable gelatin microparticles as delivery systems for the controlled release of bone morphogenetic protein-2. Acta Biomater. 2008, 4:1126-1138.
9. Ninan G., Jose J., Abubacker Z. Preparation and characterization of gelatin extracted from the skins of rohu (Labeo Rohita) and common carp (Cyprinus Carpio). J. Food Process Preserv. 2010, 35:143-162.
10. Kommareddy S., Shenoy D.B., Amiji M.M. Gelatin nanoparticles and their biofunctionalization. Nanotechnologies for the Life Sciences 2005, 1:330-352. Biofunctionalization of nanomaterials, WILY-VCH Verlag Gmb H, Co. KGaA, Weinheim.
11. Wang H.O.C., Boerman K., Sariibrahimoglu Y., Li J.A., Jansen S.C.G., Leeuwenburgh Comparison of micro-vs. nano-structured colloidal gelatin gels for sustained delivery of osteogenic proteins: bone morphogenetic protein-2 and alkaline phosphatase. Biomaterials 2012, 33:8695-8703.
12. Zwiorek K., Kloeckner J., Wagner E., Coester C. Gelatin nanoparticles as a new and simple gene delivery system. J. Pharm. Pharm. Sci. 2005, 7:22-28.
13. Busch S., Schwarz U., Kniep R. Chemical and structural investigations of Biomimetically Grown Fuorapatite-Gelatin Composite Aggregates. Adv. Funct. Mater. 2003, 13:189-198.
14. Elzoghby A.O. Gelatin-based nanoparticles as drug and gene delivery systems: Reviewing three decades of research. J. Control. Release. 2013, 172:1075-1091.
15. Flory P.J., Weaver E.S. Helix-coil transitions in dilute aqueous collagen solutions. J. Am. Chem. Soc. 1960, 82:4518-4525.
16. Akhter K.F., Zhu J., Zhang J. Nanoencapsulation of protein drug for controlled release. J. Phys. Chem. Biophys. S 2011, 11:1-5.
17. Azarmi S., Huang Y., Chen H., Quarrie S.M., Abrams D., Roa W., et al. Optimization of a two-step desolvation method for preparing gelatin nanoparticles and cell uptake studies in 143B osteosarcoma cancer cells. J. Pharm. Pharm. Sci. 2006, 9:124-132.
18. Narayanan D., Geena M.G., Lakshmi H., Koyakutty M., Nair S., Menon D. Poly-(ethylene glycol) modified gelatin nanoparticles for sustained delivery of the anti-inflammatory drug Ibuprofen-Sodium: An in vitro and in vivo analysis. Nanomedicine 2013, 9:818-828.
19. Karthikeyana S., Prasada N.R., Ganamani A., Balamurugana E. Anticancer activity of resveratrol-loaded gelatin nanoparticles on NCI-H460 non-small cell lung cancer cells. Biomed. Prev. Nutr. 2013, 3:64-73.
20. Coester C., Kreuter J., Briesen H.V., Langer K. Preparation of avidin-labelled gelatin nanoparticles as carriers for biotinylated peptide nucleic acid (PNA). Int. J. Pharm. 2000, 196:147-149.
21. Zwiorek K. Gelatin nanoparticles as delivery system for nucleotide-based drugs, in department of pharmacy, pharmaceutical technology and biopharmaceutics 2006, Ludwig-Maximilians-University München, Ph.D. dissertation.
22. Zillies J.C. Gelatin nanoparticles for targeted oligonucleotide delivery to Kupffer cells-analytics, formulation development, practical application, in department of pharmacy, pharmaceutical technology and biopharmaceutics 2007, Ludwig-Maximilians-University München, Ph.D. dissertation.
23. Farrugia C.A., Groves M.J. Gelatin behaviour in dilute aqueous solution: designing a nanoparticulate formulation. J. Pharm. Pharmacol. 1999, 51:643-649.
24. Mohanty B., Bohidar H.B. Systematic of alcohol-induced simple coacervation in aqueous gelatin solutions. Biomacromolecules 2003, 4:1080-1086.
25. Marty J.J., Oppenheim R.C., Speiser P. Nanoparticles-a new colloidal drug delivery system. Pharm. Acta Helv. 1978, 53:17-23.
26. Leo E., Vandelli M.A., Cameroni R., Forni F. Doxorubicin-loaded gelatin nanoparticles stabilized by glutaraldehyde: Involvement of the drug in the cross-linking process. Int. J. Pharm. 1997, 155:75-82.
27. Cascone M.G., Lazzeri L., Zhu Z. Gelatin nanoparticles prepared by a simple W/O emulsion as delivery system for methotrexate. J. Mater. Sci. Mater. Med. 2002, 13:523-526.
28. Bajpai A.K., Choubey J. Design of gelatin nanoparticles as swelling controlled delivery system for chloroquine phosphate. J. Mater. Sci. Mater. Med. 2006, 17:345-358.
29. Bajpai A.K., Choubey J. In vitro release dynamics of an anticancer drug from swellable gelatin nanoparticles. J. Appl. Polym. Sci. 2006, 101:2320-2332.
30. Choubey J., Bajpai A.K. Investigation on magnetically controlled delivery of doxorubicin from super paramagnetic nanocarriers of gelatin crosslinked with genipin. J. Mater. Sci. Mater. Med. 2010, 21:1573-1586.
31. Rao J.P., Geckeler K.E. Polymer nanoparticles: Preparation techniques and size control parameters. Prog. Poly. Sci. 2011, 36:887-913.
32. Pinto R.C., Neufeld R.J., Ribeiro A.J., Veiga F. Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine 2006, 2:8-21.
33. Zhao Y.Z., Li X., Lu C.T., Xu Y.Y., Lv H.F., Dai D.D., et al. Experiment on the feasibility of using modified gelatin nanoparticles as insulin pulmonary administration system for diabetes therapy. Acta Diabetol. 2012, 49:315-325.
34. Gupta A.K., Gupta M., Yarwood S.J., Curtis A.S.G. Effect of cellular uptake of gelatin nanoparticles on adhesion, morphology and cytoskeleton organization of human fibroblasts,. J. Control. Release 2004, 95:197-207.
35. Hou M.J., Kim M., Shah D.O. A light scattering study on the droplet size and inter droplet interaction in microemulsion of AOT-oil water systems. J. Colloid Interface Sci. 1998, 123:398-412.
36. Fessi H., Puisieux F., Devissaguet J.P., Ammoury N., Benita S. Nanocapsule formation by interfacial deposition following solvent displacement. Int. J. Pharm. 1989, 55:R1-R4.
37. Barichello J.M., Morishita M., Takayama K., Nagai T. Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method. Drug Dev. Ind. Pharm. 1999, 25:471-476.
38. Rodriguez S.G., Allemann E., Fessi H., Doelker E. Physicochemical parameters associated with nanoparticles formation in the salting-out, emulsification-diffusion, and nanoprecipitation methods,. Pharm Res. 2004, 21:1428-1439.
39. Ganachaud F., Katz J.L. Nanoparticles and nanocapsules created using the ouzo effect: Spontaneous emulsification as an alternative to ultrasonic and high-shear devices. Chem. Phys. Chem. 2005, 6:209-216.
40. Guerrero D.Q., Allemann E., Fessi H., Doelker E. Preparation techniques and mechanisms of formation of biodegradable nanoparticles from preformed polymers. Drug Dev. Ind. Pharm. 1998, 24:1113-1128.
41. Lee E.J., Khan S.A., Park J.K., Lim K.H. Studies on the characteristics of drug- loaded gelatin nanoparticles prepared by nanoprecipitation. Bioprocess Biosyst. Eng. 2012, 35:297-307.
42. Bilati U., Allemann E., Doelker E. Development of a nanoprecipitation method intended for the entrapment of hydrophilic drugs into nanoparticles. Eur. J. Pharm. Sci. 2005, 24:67-75.
43. Khan S.A., Schneider M. Improvement of nanoprecipitation technique for preparation of gelatin nanoparticles and potential macromolecular drug loading. Macromol. BioSci. 2013, 13:455-463.
44. Allemann E., Leroux J.C., Gurny R. Polymeric nano-microparticles for the oral delivery of peptides and peptidomimetics. Adv. Drug Deliv Rev. 1998, 34:171-189.
45. Memisoglu E., Bochot A., Ozalp M., Sen M., Duchene D., Hincal A.A. Direct formation of nanospheres from amphiphilic beta-cyclodextrin inclusion complexes. Pharm. Res. 2003, 20:117-125.
46. Fung S.Y., Yang H., Chen P. Formation of colloidal suspension of hydrophobic compounds with an amphiphilic self-assembling peptide. Colloids Surf. B 2007, 55:200-211.
47. Kim K.J., Byun Y. Preparation and characterizations of self-assembled PEGylated gelatin nanoparticles. Biotechnol. Bioprocess Eng. 1999, 4:210-214.
48. Li W.M., Liu D.M., Chen S.Y. Amphiphilically modified gelatin nanoparticles: self- assembly behaviour, controlled biodegradability, and rapid cellular uptake for intracellular drug delivery. J. Mater. Chem. 2011, 21:12381-12388.
49. Won Y.W., Yoon S.M., Sonn C.H., Lee K.M., Kim Y.H. Nano self-assembly of recombinant human gelatin conjugated with α-tocopheryl succinate for Hsp90 inhibitor 17-AAG, delivery. ACS Nano 2011, 5:3839-3848.
50. Tanigo T., Takaoka R., Tabata Y. Sustained release of water-insoluble simvastatin from Biodegradable hydrogel augments bone regeneration. J. Control. Release 2010, 143:201-206.
51. Han S., Li M., Liu X., Gao H., Wu Y. Construction of amphiphilic copolymer nanoparticles based on gelatin as drug carriers for doxorubicin delivery. Colloids Surf. B 2013, 102:833-841.
52. Chen Y.C., Yu S.H., Tsai G.J., Tang D.W., Mi F.L., Peng Y.P. Novel technology for the preparation of self-assembled catechin/gelatin nanoparticles and their characterization. J. Agric. Food Chem. 2010, 58:6728-6734.
53. Li Z., Gu L. Effects of mass ratio, pH, temperature, and reaction time on fabrication of partially purified pomegranate ellagitannins-gelatin nanoparticles. J. Agric. Food Chem. 2011, 59:4225-4231.
54. Desai M.P., Labhasetwar V., Walter E., Levy R.J., Amidon G.L. The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm. Res. 1997, 14:1568-1573.
55. Mahapatro A., Singh D.K. Biodegradable nanoparticles are excellent vehicle for site directed in vivo delivery of drugs and vaccines. J. Nanobiotechnol. 2011, 9:1-11.
56. Desai M.P., Labhasetwar V., Amidon G.L., Levy R.J. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm. Res. 1996, 13:1838-1845.
57. Zauner W., Farrow N.A., Haines A.M. In vitro uptake of polystyrene microspheres: effect of particles size, cell line and cell density,. J. Control. Release 2001, 71:39-51.
58. Moghimi S.M., Hunter A.C., Murray J.C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 2001, 53:283-318.
59. Barbé C., Bartlett J., Kong L., Finnie K., Lin H.Q., Larkin M., et al. Silica particles: a novel drug-delivery system. Adv. Mater. 2004, 16:1-8.
60. Guan J., He H., Yu B., Lee L.J. Polymeric nanoparticles nanopore membranes for controlled drug gene delivery. Biomedical Nanostructures 2007, 115-137. Wiley-Inter science, Hoboken NJ. K. in:, C. Gonsalves, C.T. Halberstadt, L. Laurencin, Nair (Eds.).
61. Nahar M., Mishra D., Dubey V., Jain N.K. Development, characterization, and toxicity evaluation of amphotericin B-loaded gelatin nanoparticles. Nanomedicine 2008, 4:252-261.
62. Won Y.W., Kim Y.H. Preparation and cytotoxicity comparison of type A gelatin nanoparticles with recombinant human gelatin nanoparticles. Macromol. Res. 2009, 17:464-468.
63. Ofokansi K., Winter G., Fricker G., Coester C. Matrix-loaded biodegradable gelatin nanoparticles as new approach to improve drug loading and delivery. Eur. J. Pharm. Biopharm. 2010, 76:1-9.
64. Maya I.J.A., Lopez J.O.R., Mazon M.C., Lopez G.F.G., Arana A.H., Nunez C.T., et al. Effect of different treatments on the ability of alpha lactalbumin to form nanoparticles. J. Dairy Sci. 2012, 95:6204-6214.
65. Storp B., Engel A., Boeker A., Ploeger M., Langer K. Albumin nanoparticles with predictable size by desolvation procedure. J. Microencapsul. 2012, 29:138-146.
66. Sailaja A.K., Amareswar P. Preparation of BSA nanoparticles by desolvation technique using acetone as desolvating agent. Int. J. Pharm. Sci. Nanotech. 2012, 5:1643-1647.
67. Zhao B., Xie J., Zhao J. A novel water-soluble nanoparticles of hypocrellin B and their interaction with a model protein: C-phycocyanin. Biochem. Biophys. Acta 2004, 1670:113-120.
68. Saxena A., Sachin K., Bohidar H.B., Verma A.K. Effect of molecular weight heterogeneity on drug encapsulation efficiency of gelatin nanoparticles. Colloids Surf. B 2005, 45:42-48.
69. Reis C.P., Neufeld R.J., Ribeiro A.J., Feiga V. Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine 2006, 2:8-21.
70. Reis C.P., Neufeld R.J., Ribeiro A.J., Veiga F. Nanoencapsulation II. Biomedical applications and current status of peptide and protein nanoparticulate delivery systems,. Nanomedicine 2006, 2:53-65.
71. Lai P., Daear W., Löbenberg R., Prenner E.J. Overview of the preparation of organic polymeric nanoparticles for drug delivery based on gelatine, chitosan, poly(d, l-lactide-co-glycolic acid) and polyalkylcyanoacrylate. Colloids Surf. B 2014, 118:154-163.
72. Kaur A., Jain S., Tiwary A.K. Mannan-coated gelatin nanoparticles for sustained and. targeted delivery of didanosine: in vitro and in vivo evaluation. Acta Pharm. 2008, 58:61-74.
73. Dixit N., Vaibhav K., Pandey R.S., Jain U.K., Katare O.P., Katyal A., Madan J. Improved cisplatin delivery in cervical cancer cells by utilizing folate-grafted non-aggregated gelatin nanoparticles. Biomed. Pharmacother. 2015, 69:1-10.
74. Singh V., Chaudhary A.K. Development and characterization of rosiglitazone loaded. gelatin nanoparticles using two step desolvation method. Int. J. Pharm. Sci. Review Res. 2010, 5:100-113.
75. Nahar M., Dubey V., Mishra D., Mishra P.K., Dube A., Jain N.K. In vitro evaluation of surface functionalized gelatin nanoparticles for macrophage targeting in the therapy of visceral leishmaniasis. J. Drug Target. 2010, 18:93-105.
76. Dhanya N., Geena M.G., Lakshmi H., Manzoor K., Shantikumar N., Deepthy M. Poly-(ethylene glycol) modified gelatin nanoparticles for sustained delivery of the anti-inflammatory drug Ibuprofen-Sodium: An in vitro and in vivo analysis. Nanomedicine 2013, 9:818-828.
77. Lu Z., Yeh T.K., Tsai M., Au J.L., Wientjes M.G. Paclitaxel-loaded gelatin nanoparticles for intravesical bladder cancer therapy. Clin. Cancer Res. 2004, 10:76-77.
78. Vandervoortand J., Ludwig A. Preparation and evaluation of drug-loaded gelatin. nanoparticles for topical ophthalmic use. Eur. J. Pharm. Biopharm. 2004, 57:251-261.
79. Karthikeyan S., Hoti S.L., Prasad N.R. Resveratrol loaded gelatin nanoparticles synergistically inhibits cell cycle progression and constitutive NF-kappa B activation, and induces apoptosis in non-small cell lung cancer cells. Biomed. Pharmacother. 2015, 70:274-282.
80. Li J.K., Wang N., Wu X.S. Gelatin nanoencapsulation of protein/peptide drugs using an emulsifier-free emulsion method. J. Microencapsul. 1998, 15:163-172.
81. Bajpai A., Choubey J. Release study of sulphamethoxazole controlled by swelling of. gelatin nanoparticles and drug-biopolymer interaction. J. Macromol. Sci. Pure Appl. Chem. 2005, 42:253-275.
82. Shabouri M.H.E. Positively charged nanoparticles for improving the oral bioavailability of cyclosporin-A. Int. J. Pharm. 2002, 249:101-108.
83. Kim M., Baek I. Fabrication and evaluation of valsartan-polymer-surfactant composite nanoparticles by using the supercritical anti-solvent process. Int. J. Nanomed. 2014, 9:5167-5176.
84. Patel J., Dhingani A., Garala K., Raval M., Sheth N. Design and development of solid nanoparticulate dosage forms of telmisartan for bioavailability enhancement by integration of experimental design and principal component analysis. Powder Technol. 2014, 258:331-343.
85. Le V.L.T., August J.T., Leong K.W. Controlled gene delivery by DNA-gelatin nanospheres. Hum. Gene Ther. 1998, 9:1709-1717.
86. Rose J.B., Pacelli S., Haj A.J.E., Dua H.S., Hopkinson A., White L.J., Rose F.R.A.J. Gelatin-based materials in ocular tissue engineering. Materials 2014, 7:3106-3135.
87. Hans M.L., Lowman A.M. Biodegradable nanoparticles for drug delivery and targeting. Curr. Opin. Solid State Mater. Sci. 2002, 6:319-327.
88. Mahapatro A., Johnson D.M., Patel D.N., Feldman M.D., Ayon A.A., Agrawal C.M. Drug delivery from therapeutic self-assembled monolayers (T-SAMs) on 316L stainless steel. Curr. Topics Med. Chem. 2008, 8:281-289.
89. Gaihrea B., Khil M.S., Lee D.R., Kim H.Y. Gelatin coated magnetic iron oxide nanoparticles as carrier system: Drug loading and in vitro drug release study. Int. J. Pharm. 2009, 365:180-189.
90. Kim D., Shall H.E., Dennis D., Morey T. Interaction of PLGA nanoparticles with human blood constituents. Colloids Surf. B 2005, 40:83-91.
91. Gref R., Lück M., Quellec P., Marchand M., Dellacherie E., Harnisch S., et al. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf. B 2000, 18:301-313.
92. Gref R., Couvreur P., Barratt G., Mysiakine E. Surface-engineered nanoparticles for multiple ligand coupling. Biomaterials 2003, 24:4529-4537.
93. Kommareddy S., Amiji M. Preparation and evaluation of thiol-modified gelatin nanoparticles for intracellular DNA delivery in response to glutathione. Bioconjuq. Chem. 2005, 16:1423-1432.
94. Kommareddy S., Amiji M. Poly (ethylene glycol) modified thiolated gelatin nanoparticles for glutathione responsive intracellular DNA delivery. Nanomedicine 2007, 3:32-42.
95. Otsuka H., Nagasaki Y., Kataoka K. PEGylated nanoparticles for biological and pharmaceutical applications. Adv. Drug Deliv. Rev. 2003, 55:403-419.
96. Crawford J. Clinical uses of PEGylated pharmaceuticals in oncology. Cancer Treat. Rev. 2002, 28:7-11.
97. Xu J., Ganesh S., Amiji M. Non-condensing polymeric nanoparticles for targeted gene and siRNA delivery. Int. J. Pharm. 2012, 427:21-34.
98. Kaul G., Amiji M. Biodistribution and targeting potential of poly (ethylene glycol) - modified gelatin nanoparticles in subcutaneous murine tumor model. J. Drug Target. 2004, 12:585-591.
99. Kaul G., Amiji M. Tumor-targeted gene delivery using poly (ethylene glycol) modified gelatin nanoparticles: in vitro and in vivo studies. Pharm. Res. 2005, 22:951-961.
100. Kushibiki T., Matsuoka H., Tabata Y. Synthesis and physical characterization of Poly (ethylene glycol) gelatin conjugates. Biomacromolecules 2004, 5:202-208.
101. Kommareddy S., Amiji M. Biodistribution and pharmacokinetic analysis of long circulating thiolated gelatin nanoparticles following systemic administration in breast cancer bearing mice. J. Pharm. Sci. 2007, 96:397-407.
102. Lee G.Y., Park K., Nam J.H., Kim S.Y., Byun Y. Anti-tumor and anti-metastatic effects of gelatin doxorubicin and PEGylated gelatin doxorubicin nanoparticles in SCC7 bearing mice. J. Drug Target. 2006, 14:707-716.
103. Babu A., Periasamy J., Gunasekaran A., Kumaresan G., Naicker S., Gunasekaran P., Murugesan R. Polyethylene glycol-modified gelatin/polylactic acid nanoparticles for enhanced photodynamic efficacy of a hypocrellin derivative in vitro. J. Biomed. Nanotechnol. 2013, 9:177-192.
104. Xu X., Capito R.M., Spector M. Delivery of plasmid IGF-1 to chondrocytes via cationized gelatin nanoparticles. J. Biomed. Mater. Res. 2008, 84:73-83.
105. Kuo W.T., Huang H.Y., Chou M.J., Wu M.C., Huang Y.Y. Surface modification of gelatin nanoparticles with polyethylenimine as gene vector. J. Nanomater. 2011, 2011:1-5.
106. Ishikawa H., Nakamura Y., Jo J., Tabata Y. Gelatin nanospheres incorporating siRNA for controlled intracellular release. Biomaterials 2012, 33:9097-9104.
107. Mimi H., Ho K.M., Siu Y.S., Wu A., Li P. Polyethyleneimine based core shell nanogels: a promising siRNA carrier for argininosuccinate synthetase mRNA knock down in HeLa cells. J. Control. Release 2012, 158:123-130.
108. Coester C., Nayyar P., Samuel J. In vitro uptake of gelatin nanoparticles by murine dendritic cells and their intracellular localization. Eur. J. Pharm. Biopharm. 2006, 62:306-314.
109. Guilatt L.R., Couvreur P., Lambert G., Dubernet C. Cationic vectors in ocular drug delivery. J. Drug Target. 2004, 12:623-633.
110. Zorzi G.K., Párraga J.E., Seijo B., Sánchez A. Hybrid nanoparticle design based on cationized gelatin and the polyanions dextran sulfate and chondroitin sulfate for ocular gene therapy. Macromol. Biosci. 2011, 11:905-913.
111. Weigel J.A., Weigel P.H. Characterization of the recombinant rat 175-kDa hyaluronan receptor for endocytosis (HARE). J. Biol. Chem. 2003, 278:42802-42811.
112. Uesugi Y., Kawata H., Jo J., Saito Y., Tabata Y. An ultrasound-responsive nano delivery system of tissue-type plasminogen activator for thrombolytic therapy. J. Control. Release 2010, 147:269-277.
113. Uesugi Y., Kawata H., Saito Y., Tabata Y. Ultrasound-responsive thrombus treatment. with zinc-stabilized gelatin nano-complexes of tissue-type plasminogen activator. J. Drug Target. 2012, 20:224-234.
114. Balthasar S., Michaelis K., Dinauer N., Briesen H.V., Kreuter J., Langer K. Preparation and characterization of antibody modified gelatin nanoparticles as drug carrier system for uptake in lymphocytes. Biomaterials 2005, 26:2723-2732.
115. Dinauer N., Balthasar S., Weber C., Kreuter J., Langer K., Briesen H.V. Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T- lymphocytes. Biomaterials 2005, 26:5898-5906.
116. Li Z., Zhao R., Wu X., Sun Y., Yao M., Li J., et al. Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics. FASEB J. 2005, 19:1978-1985.
117. Magadala P., Amiji M. Epidermal growth factor receptor-targeted gelatin-based engineered nanocarriers for DNA delivery and transfection in human pancreatic cancer cells. AAPS J. 2008, 10:565-576.
118. Xu J., Amiji M. Therapeutic gene delivery and transfection in human pancreatic cancer cells using epidermal growth factor receptor targeted gelatin nanoparticles. J. Vis. Exp. 2012, 59:612.
119. Xu J., Gattacceca F., Amiji M. Biodistribution and pharmacokinetics of EGFR- targeted thiolated gelatin nanoparticles following systemic administration in pancreatic tumor-bearing mice. Mol. Pharm. 2013, 10:2031-2044.
120. Tseng C.L., Su W.Y., Yen K.C., Yang K.C., Lin F.H. The use of biotinylated-EGF- modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation. Biomaterials 2009, 30:3476-3485.
121. Tseng C.L., Wu S.Y.H., Wang W.H., Peng C.L., Lin F.H., Lin C.C., et al. Targeting efficiency and biodistribution of biotinylated-EGF-conjugated gelatin nanoparticles administered via aerosol delivery in nude mice with lung cancer. Biomaterials 2008, 29:3014-3022.
122. Drin G., Cottin S., Blanc E., Rees A.R., Temsamani J. Studies on the internalization mechanism of cationic cell-penetrating peptides. J. Biol. Chem. 2003, 278:31192-31201.
123. Wei B., Wei Y., Zhang K., Wang J., Xu R., Zhan S., et al. Development of an antisense RNA delivery system using conjugates of the MS2 bacteriophage capsids and HIV-1 TAT cell-penetrating peptide. Biomed. Pharmacother. 2009, 63:313-318.
124. Tian X.H., Wei F., Wang T.X., Wang D., Wang J., Lin X.N., et al. Blood-brain barrier transport of Tat peptide and polyethylene glycol decorated gelatin-siloxane nanoparticle. Mater. Lett. 2012, 68:94-96.
125. Tian X.H., Wei F., Wang T.X., Wang P., Lin X.N., Wang J., et al. In vitro and in vivo studies on gelatin-siloxane nanoparticles conjugated with SynB peptide to increase drug delivery to the brain. Int. J. Nanomed. 2012, 7:1031-1041.
126. Tian X.H., Wang Z.G., Meng H., Wang Y.H., Feng W., Wei F., et al. Tat peptide decorated gelatin-siloxane nanoparticles for delivery of CGRP transgene in treatment of cerebral vasospasm. Int. J. Nanomed. 2013, 8:865-876.
127. Nimje N., Agarwal A., Saraogi G.K., Lariya N., Rai G., Agrawal H., Agrawal G.P. Mannosylated nanoparticulate carriers of rifabutin for alveolar targeting. J. Drug Target. 2009, 17:777-787.
128. Jain S.K., Gupta Y., Jain A., Saxena A.R., Khare P., Jain A. Mannosylated gelatin nanoparticles bearing an anti-HIV drug didanosine for site-specific delivery. Nanomedicine 2008, 4:41-48.
129. Saraogi G.K., Sharma B., Joshi B., Gupta P., Gupta U.D., Jain N.K., Agrawal G.P. Mannosylated gelatin nanoparticles bearing isoniazid for effective management of tuberculosis. J. Drug Target. 2011, 19:219-227.
130. Garg M., Madan J., Pandey R.S., Sardana S., Katyal A., Chandra R. Galactosylated Gelatinnanovectors of doxorubicin inhibit cell proliferation and induce apoptosis in hepatocarcinoma cells. Anticancer Drugs 2012, 23:836-845.
131. Elbert S., Hubbell J.A. Development of fibrin derivatives for controlled release of heparin-binding growth factors. J. Control. Release 2000, 65:389-402.
132. Jain A., Gulbake A., Jain A., Shilpi S., Hurkat P., Jain A., Jain S.K. Development of surface-functionalised nanoparticles for FGF2 receptor-based solid tumour targeting. J. Microencapsul. 2012, 29:95-102.
133. Sarkar D. Fabrication of an optimized fluorescer encapsulated polymer coated gelatin nanoparticle and study of its retarded release properties. J. Photochem. Photobiol. 2013, 252:194-202.
134. Madan J., Dhiman N., Sardana S., Aneja R., Chandra R., Katyal A. Long-circulating poly (ethylene glycol) grafted gelatin nanoparticles customized for intracellular delivery of noscapine: preparation, in-vitro characterization, structure elucidation, pharmacokinetics, and cytotoxicity analysis. Anticancer Drugs 2011, 22:543-555.
135. McGhee J.R., Mestecky J., Dertzbaugh M.T., Eldridge J.H., Hirasawa M., Kiyono H. The mucosal immune system: from fundamental concepts to vaccine development. Vaccine 1992, 10:75-88.
136. Mestecky J., McGhee J.R. Immunoglobulin A (IgA): molecular and cellular interactions involved in IgA biosynthesis and immune response. Adv. Immunol. 1987, 40:153-245.
137. Brzoska M., Langer K., Coester C., Loitsch S., Wagner T.O.F., Mallinckrodt C.V. Incorporation of biodegradable nanoparticles into human airway epithelium cells in vitro study of the suitability as a vehicle for drug or gene delivery in pulmonary diseases. Biochem. Biophy. Res. Commun. 2004, 318:562-570.
138. Illum L., Gill I.J., Hinchcliffe M., Fisher A.N., Davis S.S. Chitosan as a novel nasal delivery system for vaccines. Adv. Drug Deliv. Rev. 2001, 51:81-96.
139. Regnstrom K., Ragnarsson E.G., Hoggard M.K., Torstensson E., Nyblom H., Artursson P. PEI- a potent, but not harmless, mucosal immuno-stimulator of mixed T-helper cell response and FasL- mediated cell death in mice. Gene Ther. 2003, 10:1575-1583.
140. Gurunathan S., Wu C.Y., Freidag B.L., Seder R.A. DNA vaccines: a key for inducing long-term cellular immunity. Curr. Opin. Immunol. 2000, 12:442-447.
141. Schwick H.G., Heide K. Immunochemistry and immunology of collagen and gelatin. Bibl. Haematol. 1969, 3:111-125.
142. Mladenovska K., Kumbaradzi E.F., Dodov G.M., Makraduli L., Goracinova K. Biodegradation and drug release studies of BSA loaded gelatin microspheres. Int. J. Pharm. 2002, 242:247-249.
143. Nakaoka R., Tabata Y., Ikada Y. Potentiality of gelatin microspheres as immunological adjuvant. Vaccine 1995, 13:653-661.
144. Cesta M.F. Normal structure, function, and histology of mucosa-associated lymphoid tissue. Toxicol. Pathol. 2006, 34:599-608.
145. Li J.K., Wang N., Wu X.S. A novel biodegradable system based on gelatin nanoparticles and Poly (lactic-co-glycolic acid) microspheres for protein and peptide drug delivery. J. Pharm. Sci. 1997, 86:891-895.
146. Won Y.W., Kim Y.H. Recombinant human gelatin nanoparticles as a protein drug carrier. J. Control. Release 2008, 127:154-161.
147. Wang H., Zou Q., Boerman O.C., Nijhuis A.W.G., Jansen J.A., Li Y., Leeuwenburgh S.C.G. Combined delivery of BMP-2 and bFGF from nanostructured colloidal gelatin gels and its effect on bone regeneration in vivo. J. Control. Release 2013, 166:172-181.
148. Sudheesh M.S., Vyas S.P., Kohli D.V. Nanoparticle-based immunopotentiation via tetanus toxoid loaded gelatin and aminated gelatin nanoparticles. Drug Deliv. 2011, 18:320-330.
149. Sakai Y., Yamato R., Onuma M., Kikuta T., Watanabe M., Nakayama T. Non-antigenic and low allergic gelatin produced by specific digestion with an enzyme-coupled matrix. Biol. Pharm. Bull. 1998, 21:330-334.
150. Nomura T., Koreeda N., Yamashita F., Takakura Y., Hashida M. Effect of particle size and charge on the disposition of lipid carriers after intratumoral injection into tissue-isolated tumors. Pharm. Res. 2005, 22:128-132.
151. Tan W., Wang K., He X., Zhao X.J., Drake T., Wang L., et al. Bionanotechnology based on silica nanoparticles. Med. Res. Rev. 2004, 24:621-638.
152. Kneuer C., Sameti M., Bakowsky U., Schiestel T., Schirra H., Schmidt H., et al. A non-viral DNA delivery system based on surface modified silica-nanoparticles can efficiently transfect cells in vitro. Bioconjug. Chem. 2000, 11:926-932.
153. Kneuer C., Sameti M., Haltner E.G., Schiestel T., Schirra H., Schmidt H., et al. Silica nanoparticles modified with aminosilanes as carriers for plasmid DNA. Int. J. Pharm. 2000, 196:257-261.
154. Panyam J., Zhou W.Z., Prabha S., Sahoo S.K., Labhasetwar V. Rapid endolysosomal escape of poly (DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J. 2002, 16:1217-1226.
155. Hedley M.L., Curley J., Urban R. Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses. Nat. Med. 1998, 4:365-368.
156. Zwiorek K., Bourquin C., Battiany J., Winter G., Endres S., Hartmann G., Coester C. Delivery by cationic gelatin nanoparticles strongly increases the immunostimulatory effects of CpG oligonucleotides. Pharm. Res. 2008, 25:551-562.
157. He X., Wang K., Tan W., Liu B., Liu X., Huang S., et al. Bioconjugated nanoparticles for DNA protection from cleavage. J. Am. Chem. Soc. 2003, 125:7168-7169.
158. Singh M., Briones M., Ott G., Hagan D. Cationic microparticles: A potent delivery system for DNA Vaccine. Proc. Natl. Acad. Sci. 2000, 97:811-816.
159. Reszka R., Zhu J.H., Weber F. Liposome mediated transfer of marker and cytokine genes into rat and human Glio-blastoma, cells in vitro and in vivo. J. Liposome Res. 1995, 5:149-154.
160. Junghans M., Kreuter J., Zimmer A. Antisense delivery using protamine-oligonucleotide particles. Nucleic Acids Res. 2000, 28:E45.
161. Schwab G., Chavany C., Duroux I., Goubin G., Lebeau J., Helene C., et al. Antisense oligonucleotides adsorbed to polyalkyl cyanoacrylate nanoparticles specifically inhibit mutated Ha-ras-mediated cell proliferation and tumorigenicity in nudemice. Proc. Natl. Acad. Sci. 1994, 22:10460-10464.
162. Erbacher P., Zou S., Bettinger T., Steffan A.M., Remy J.S. Chitosan-based vector/DNA complexes for gene delivery: biophysical characteristics and transfection ability. Pharm. Res. 1998, 15:1332-1339.
163. Leong K.W., Mao H.Q., Le V.L.T., Roy K., Walsh S.M., August J.T. DNA Polycation nanospheres as non-viral gene delivery vehicles. J. Control. Release 1998, 53:183-193.
164. Kaul G., Amiji M. Long-circulating poly (ethylene glycol)- modified gelatin nanoparticles for intracellular delivery. Pharm. Res. 2002, 19:1062-1068.
165. Kaul G., Amiji M. Protein nanospheres for gene delivery, In Polymeric Gene Delivery: Principles and applications 2004, 429-447. Ed. CRC Press, Boca Raton FL.
166. Kaul G., Amiji M. Long-circulating poly (ethylene glycol)-modified gelatin nanoparticles for intracellular delivery. Pharm. Res. 2002, 19:1061-1067.
167. Kaul G., Parsons C.L., Amiji M. Poly (ethylene glycol) modified gelatin nanoparticles for intra cellular delivery. Pharm. Eng. 2003, 23:108-114.
168. Kaul G., Amiji M. Cellular interactions and in vitro DNA transfection studies with poly (ethylene glycol)-modified gelatin nanoparticles. J. Pharm. Sci. 2005, 94:184-198.
169. Nezhadi S.H., Valizadeh H., Baradaran B., Dobakhti F., Lotfipour F. preparation and characterization of gelatin nanoparticles containing pDNA encoding IL-12 and their expression in CT-26 carcinoma cells. Future Oncol. 2013, 9:1195-1206.
170. S. Shah, Hypoxia in Tumor Angiogenesis and Metastasis: Evaluation of VEGF and MMP Over-Expression and Down-Regulation of HIF-1α with RNAi in Hypoxic Tumor Cells, 2010 (Master's Thesis).
171. Bhavsar M.D., Tiwari S.B., Amiji M.M. Formulation optimization for the nanoparticles-in-microsphere hybrid oral delivery system using factorial design. J. Control. Release 2006, 110:422-430.
172. Bhavsar M.D., Amiji M.M. Gastrointestinal distribution and in vivo gene transfection studies with nanoparticles-in-microsphere oral system (NiMOS). J. Control. Release 2007, 119:339-348.
173. Bhavsar M.D., Amiji M.M. Development of novel biodegradable polymeric nanoparticles-in-microsphere formulation for local plasmid DNA delivery in the gastrointestinal tract. AAPS Pharm. Sci. Tech. 2008, 9:288-294.
174. Kriegel C., Attarwala H., Amiji M. Multi-compartmental oral delivery systems for nucleic acid therapy in the gastrointestinal tract. Adv. Drug Deliv. Rev. 2013, 65:891-901.
175. Kriegel C., Amiji M. Oral TNF-α gene silencing using a polymeric microsphere based delivery system for the treatment of inflammatory bowel disease. J. Control. Release 2011, 150:77-86.
176. Zorzi G.K., Ruiz L.C., Párraga J.E., García A.L., Bello R.R., Diebold Y., et al. Expression of MUC5AC in ocular surface epithelial cells using cationized gelatin nanoparticles. Mol. Pharm. 2011, 8:1783-1788.
177. Sham J.O.H., Zhang Y., Finlay W.H., Roa W.H., Löbenberg R. Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung. Int. J. Pharm. 2004, 269:457-467.
178. Fuchs S., Klier J., May A., Winter G., Coester C., Gehlen H. Towards an inhalative in vivo application of immunomodulating gelatin nanoparticles in horse-related pre formulation studies. J. Microencapsul. 2012, 29:615-625.
179. Klier J., Fuchs S., May A., Schillinger U., Plank C., Winter G., et al. An ebulized gelatin nanoparticle-based CpG formulation is effective in immune therapy of allergic horses. Pharm. Res. 2012, 29:1650-1657.
180. Sagar S.M., Yance D., Wong R.K. Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer-Part 1. Curr. Oncol. 2006, 13:14-26.
181. Shutava T.G., Balkundi S.S., Vangala P., Steffan J.J., Bigelow R.L., Cardelli J.A., et al. Layer-by-layer-coated gelatin nanoparticles as a vehicle for delivery of natural polyphenols. ACS Nano 2009, 3:1877-1885.
182. Zhou H., Sun X., Zhang L., Zhang P., Li J., Liu Y.N. Fabrication of bio-polymeric complex coacervation core micelles for efficient tea polyphenol delivery via a green process. Langmuir 2012, 28:14553-14561.
183. Zou T., Percival S.S., Cheng Q., Li Z., Rowe C.A., Gu L. Preparation, characterization, and induction of cell apoptosis of cocoa procyanidins-gelatin-chitosan nanoparticles. Eur. J. Pharm. Biopharm. 2012, 82:36-42.
184. Jain D., Banerjee R. Comparison of ciprofloxacin hydrochloride-loaded protein, lipid, and chitosan nanoparticles for drug delivery. J. Biomed. Mater. Res. B Appl. Biomater. 2008, 86:105-112.
185. Kuntworbe N., Ofori M., Addo P., Tingle M., Kassas R.A. Pharmacokinetics and in vivo chemo-suppressive activity studies on cryptolepine hydrochloride and cryptolepine hydrochloride-loaded gelatin nano formulation designed for parenteral administration for the treatment of malaria. Acta Trop. 2013, 127:165-173.
186. Kumar R., Nagarwal R.C., Dhanawat M., Pandit J.K. In-vitro and in-vivo study of indomethacin loaded gelatin nanoparticles. J. Biomed. Nanotechnol. 2011, 7:325-333.